Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Bottomley, J.
Right arrow Articles by Massi-Benedetti, M.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reviews

Review: PROactive 03: Pioglitazone, type 2 diabetes and reducing macrovascular events — economic implications?

Julia Bottomley

Amygdala Ltd, The Warren, Willian Road, Letchworth Garden City, Hertfordshire, SG6 2AA, UK, jmb{at}amygdala.uk.com

Andrew J Palmer

Amygdala Ltd, The Warren, Willian Road, Letchworth Garden City, Hertfordshire, SG6 2AA, UK

Rhys Williams

Amygdala Ltd, The Warren, Willian Road, Letchworth Garden City, Hertfordshire, SG6 2AA, UK

John Dormandy

Amygdala Ltd, The Warren, Willian Road, Letchworth Garden City, Hertfordshire, SG6 2AA, UK

Massimo Massi-Benedetti

Amygdala Ltd, The Warren, Willian Road, Letchworth Garden City, Hertfordshire, SG6 2AA, UK

conomic value of medicines, medical devices and other technologies is an increasingly important consideration in healthcare management. Conducting high quality economic analyses alongside randomised controlled clinical trials (RCTs) is desirable since these offer timely information with high internal validity. The recent publication of the landmark PROactive study provides a relevant platform upon which to base a detailed economic evaluation of the possible additional benefit of pioglitazone over and above current best treatment in patients with type 2 diabetes with severe cardiovascular (CV) disease. Pioglitazone improved CV outcome and reduced the need to add insulin to existing therapy in individuals at high risk of further macrovascular events. The predefined economic analysis of this study using well-accepted methods will inform the cost effectiveness (CE) of pioglitazone confirming (or not) its value in the management of patients with type 2 diabetes with severe CV disease.

Key Words: type 2 diabetes • pioglitazone • insulin resistance • studies • cost-effectiveness • and guidelines. cardiovascular risk • severe cardiovascular disease • outcome studies • cost-effectiveness • and guidelines.

The British Journal of Diabetes & Vascular Disease, Vol. 6, No. 2, 63-70 (2006)
DOI: 10.1177/14746514060060020401
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?